Innovation is a critical element of the strategy driving TriRx Pharmaceutical Services. In all of the work that TriRx does, it is essential to continually find new ways to incorporate new technologies, process improvements, and advanced equipment in their operations and service to their customers. The company encourages innovation, invests in development, and incorporates the Lean Six Sigma approach in everything that they do. TriRx has invested in development resources to assure incorporation of innovation in their diverse product offerings.
Recent innovations in the industry overall that have had a significant impact on how TriRx does business include formulation development, process improvements, and new processes/equipment. TriRx is focused on exploring the ways in which robotics, nanoparticle technology, controlled release technology, laser printing, on-line printing, process analytical technologies (PATs), 3D printing, quality by design (QbD), and liquid dispensing technologies can improve the company’s current offerings, and will ideally integrate new technologies to bolster ongoing services. The company is constantly seeking new innovations to improve operations and has already incorporated robotics, serialization, and cloud-based enterprise resource planning (ERP).
While there are significant bottlenecks in development, formulation manufacturing, and the supply chain that require innovative solutions, there are also significant opportunities to reduce process time, process steps, and waste throughout the entire development and manufacturing process. Continuous flow processing, 3D printing, and the application of Lean Six Sigma methodologies will have a major impact on cycle time and cost.
Due to the COVID-19 crisis, TriRx Pharmaceutical Services has seen a significant increase in demand for virus-related products. The company has had to shift production to meet these demands while focusing on taking care of their workforce. TriRx has plans to actively pursue business directly related to COVID-19 therapeutics/ vaccines in the areas of respiratory, cough/cold, pain, infectious disease, and sanitizer/microbial control products.
TriRx believes that critical innovations to address this crisis will involve vaccines, treatment medicines, and even sanitizers. One of the critical outcomes of the COVID-19 pandemic will be strategizing on how to realign critical excess capacity in manufacturing to make critically necessary products, without compromising the ability of the industry to keep supply chains robust for the wide range of other life-saving products already on the market.
.svg)
